A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Active not recruiting 127 enrolled AstraZeneca Daiichi Sankyo · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.

Timeline

Start: 2024-02-22
Primary completion: 2025-11-28
Completion: 2027-02-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	Intravenous
Subject	Trastuzumab deruxtecan	Monoclonal antibody	—	Intravenous

Indications

No indication recorded.